Merck and Kelun-Biotech say sac-TMT targeted chemotherapy cuts death risk by one-third in advanced endometrial cancer

Merck and China's Kelun-Biotech say a type of targeted chemotherapy cut by one-third the risk of death in patients with advanced endometrial cancer.

Detected & updated continuously · Source: Nebula